8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – March 4, 2010

________________________

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

_____________________

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

610-594-2900

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or address, if changed since last report)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01  Regulation FD Disclosure

In December 2009, the Company announced that it realigned its organization into two reporting segments now called “Pharmaceutical Packaging Systems” and “Pharmaceutical Delivery Systems.” The new reporting segments were effective beginning January 1, 2010. In order to assist investors in comparing 2010 performance with 2009 performance, the Company has presented unaudited 2009 quarterly and full-year segment data from its 2009 income statements as if the new reporting segments had been in effect at the beginning of 2009. A copy of this unaudited realigned segment data is attached to this report as Exhibit 99.1.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under that Act or the Securities Act of 1933.

Item 9.01  Financial Statements and Exhibits

(d)	Exhibits
	Exhibit #	Description
	99.1	West Pharmaceutical Services, Inc. Unaudited 2009 Realigned Segment Data Showing “As-If” Effect of Realignment

- 2 - -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III

Vice President, General Counsel and Secretary

March 4, 2010

- 3 - -

EXHIBIT INDEX

Exhibit No.	Description
99.1	West Pharmaceutical Services, Inc. Unaudited 2009 Re-Presented Segment Data Showing “As-If” Effect of Realignment

- 4 - -

EX-99.1

                             EXHIBIT 99.1

West Pharmaceutical Services, Inc.
($ Millions)
Presented "as if" 2010 business unit realignments were effective in 2009, in order to facilitate comparative analyses of 2010 segment results to the comparable prior-year periods
(UNAUDITED)
	2009 Consolidated Results
	Three Months Ended												Year Ended
	March 31			June 30			Sept 30			Dec 31			Dec 31
Net Sales:
Pharmaceutical Packaging Systems	$	176.4		$	190.1		$	189.9		$	219.6		$	776.0
Pharmaceutical Delivery Systems		67.5			72.1			70.2			75.2			285.0
Eliminations		(1.5	)		(1.2	)		(1.2	)		(1.4	)		(5.3	)
Consolidated Net Sales		242.4			261.0			258.9			293.4			1,055.7
Gross Profit:
Pharmaceutical Packaging Systems		56.4			62.9			59.2			72.4			250.9
Pharmaceutical Delivery Systems		12.9			15.8			12.5			11.5			52.7
Consolidated Gross Profit		69.3			78.7			71.7			83.9			303.6
Research and Development Expense:
Pharmaceutical Packaging Systems		(2.0	)		(2.1	)		(2.4	)		(2.5	)		9.0	)
Pharmaceutical Delivery Systems		(2.3	)		(2.6	)		(2.7	)		(3.3	)		(10.9	)
Consolidated Research and Development		(4.3	)		(4.7	)		(5.1	)		(5.8	)		(19.9	)
Selling, General and Administrative Expense:
Pharmaceutical Packaging Systems		(25.6	)		(25.6	)		(25.7	)		(26.2	)		(103.1	)
Pharmaceutical Delivery Systems		(7.2	)		(8.3	)		(8.1	)		(8.1	)		(31.7	)
General Corporate Costs and Other		(10.1	)		(11.2	)		(10.5	)		(11.1	)		(42.9	)
Consolidated S,G&A Expense		(42.9	)		(45.1	)		(44.3	)		(45.4	)		(177.7	)
Operating Profit:
Pharmaceutical Packaging Systems		28.9			35.4			30.9			43.1			138.3
Pharmaceutical Delivery Systems		3.1			5.0			1.6			0.2			9.9
General Corporate Costs		(4.6	)		(4.9	)		(3.7	)		(5.8	)		(19.0	)
Stock-based Compensation Expense		(1.4	)		(2.3	)		(2.5	)		(1.3	)		(7.5	)
U.S. Pension Expense		(4.1	)		(4.1	)		(4.3	)		(4.2	)		(16.7	)
Other Unallocated (Charges) Income		(0.7	)		(0.4	)		3.9			(10.3	)		(7.5	)
Consolidated Operating Profit		21.2			28.7			25.9			21.7			97.5
Interest Expense, net		(3.6	)		(3.4	)		(3.5	)		(3.9	)		(14.4	)
Income Tax Expense		(2.5	)		(6.1	)		(6.0	)		1.1			(13.5	)
Equity in Net Income of Affiliates		0.3			0.5			0.8			1.4			3.0
Net Income Attributable to Common Shareholders	$	15.4		$	19.7		$	17.2		$	20.3		$	72.6
The changes reflected in these tables relate solely to the composition of the Company's business segments, and have no impact on 2009 consolidated and per-share results included in the Company's earnings releases and forms 10Q and 10K.

1

West Pharmaceutical Services, Inc.
($ Millions)
Presented "as if" 2010 business unit realignments were effective in 2009, in order to facilitate comparative analyses of 2010 segment results to the comparable prior-year periods
(UNAUDITED)
	2009 New Segment Results - Summary
	Three Months Ended												Year Ended
	March 31			June 30			Sept 30			Dec 31			Dec 31
Pharmaceutical Packaging Systems
Net Sales	$	176.4		$	190.1		$	189.9		$	219.6		$	776.0
Gross Profit	$	56.4		$	62.9		$	59.2		$	72.4		$	250.9
Gross Margin %		32.0	%		33.1	%		31.2	%		33.0	%		32.3	%
Research and Development Expense		(2.0	)		(2.1	)		(2.4	)		(2.5	)		(9.0	)
Selling, General and Administrative Expense		(25.6	)		(25.6	)		(25.7	)		(26.2	)		(103.1	)
Operating Profit	$	28.9		$	35.4		$	30.9		$	43.1		$	138.3
% of Sales		16.4	%		18.6	%		16.3	%		19.6	%		17.8	%
Pharmaceutical Delivery Systems
Net Sales	$	67.5		$	72.1		$	70.2		$	75.2		$	285.0
Gross Profit	$	12.9		$	15.8		$	12.5		$	11.5		$	52.7
Gross Margin %		19.1	%		21.9	%		17.8	%		15.3	%		18.5	%
Research and Development Expense		(2.3	)		(2.6	)		(2.7	)		(3.3	)		(10.9	)
Selling, General and Administrative Expense		(7.2	)		(8.3	)		(8.1	)		(8.1	)		(31.7	)
Operating Profit	$	3.1		$	5.0		$	1.6		$	0.2		$	9.9
% of Sales		4.6	%		6.9	%		2.3	%		0.3	%		3.5	%
The changes reflected in these tables relate solely to the composition of the Company's business segments, and have no impact on 2009 consolidated and per-share results included in the Company's earnings releases and forms 10Q and 10K.

2